![20200212 Guidelines comparison tablev10 [online] UPDATED 2020 v4](https://d3j7puhwqgd8ts.cloudfront.net/Pictures/173x115//9/3/4/6934_20200212guidelinescomparisontablev10onlineupdated2020v4_419801.png)
Type 2 diabetes pharmacological management pathway comparison
This comparison table summarises recommendations on the management of hyperglycaemia in adults with type 2 diabetes from ADA/EASD, NICE, and SIGN.
Diabetic foot problems: prevention and management
This summary covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Guideline for the managed introduction of biosimilar basal insulin
This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of a grant from Mylan.
NICE type 2 diabetes guideline
This summary provides recommendations on blood glucose targets, patient education, and includes a useful algorithm on blood glucose management.
Type 2 diabetes: frailty in older people
Summary covers glycaemic targets for older people, priorities for improving high-quality diabetes care, and a useful frailty assessment pathway.
Educational resources
Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.
Ozempic® ▼ (semaglutide) 1.34 mg/ml once‑weekly GLP-1 RA
Commissioned by Novo Nordisk Limited